Venus Concept Shares Soar 56.48% on FDA Clearance of NOVA Platform

The share price rose to its highest level so far this month, with an intraday gain of 56.48%.

Venus Concept’s surge followed the U.S. Food and Drug Administration’s 510(k) clearance for its next-generation Venus NOVA platform, a multi-application device combining technologies such as Adaptive EMS, MP RF, and PEMF. The approval, announced on Nov. 10, positions the company to capitalize on growing demand for non-invasive treatments, particularly among patients using GLP-1 medications for weight loss. The device’s launch in December 2025 is expected to drive adoption through the Venus Jumpstart Program, a 30-day initiative offering clinics clinical and marketing support. The company also highlighted its Venus Connect™ IoT platform, which enhances operational efficiency for clinics.

Despite recent regulatory progress, the stock remains volatile amid broader financial challenges. Venus Concept has reduced debt to $30.1 million through a September 2025 restructuring but continues to report negative profitability. The recent 22.8% surge on Nov. 10 reflects optimism over NOVA’s market potential, though analysts note risks tied to the company’s leverage and execution uncertainties. The device’s focus on addressing GLP-1-related skin laxity aligns with a projected $32 million patient demographic by 2030, offering a strategic edge in a competitive sector. However, long-term success will depend on adoption rates, pricing strategies, and sustained innovation amid high debt and operational costs.